Identification | Back Directory | [Name]
diperdipine | [CAS]
108852-42-2 | [Synonyms]
YS-201 diperdipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-ethyl 5-[2-(1-piperidinyl)ethyl] ester | [Molecular Formula]
C24H31N3O6 | [MOL File]
108852-42-2.mol | [Molecular Weight]
457.52 |
Chemical Properties | Back Directory | [Boiling point ]
593.9±50.0 °C(Predicted) | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
8.29±0.10(Predicted) | [color ]
Light yellow to yellow |
Hazard Information | Back Directory | [Uses]
YS-201 is a dihydropyridine-type calcium channel antagonist. YS-201 has the potential for angina pectoris and hypertension treatment. | [in vivo]
YS-201 (Diperdipine) markedly reduces systemic vascular resistance and improves stroke index and left ventricular ejection fraction. Mean pulmonary artery and wedge pressures are slightly increased as a possible consequence of enhanced venous return, whereas right atrial and left ventricular end-diastolic pressures are not significantly changed. Nevertheless, an increase in preload is clearly indicated by an augmented left ventricular end-diastolic volume index after administration of diperdipine[1]. After intravenous and oral doses, absolute bioavailability is calculated to be 18.7%. Biliaryexcretion accounts for about 0.1% of the total clearance of diperdipine and does not contribute to the overall elimination of the drug. After intraportal administration, the bioavailable fraction of diperdipine is increasing up to 44.3% suggesting a prehepatic site of loss of the drug[2]. The single application of diperdipine to mice and rats by gavage causes intolerance reactions starting at the lowest tested dose level of 200 mg/kg b.w. p.o. (mice) and at 250 mg/kg b.w. p.o. (rats). In the rat, toxic effects occur from 15 mg diperdipine/kg b.w./day p.o. onwards[3]. | [References]
[1] Di Donato M, et al. Acute hemodynamic effects of intravenous diperdipine, a new dihydropyridine derivative, in coronary heart disease. Am Heart J. 1991 Mar;121(3 Pt 1):776-81. DOI:10.1016/0002-8703(91)90188-n [2] Greiner PO, et al. Evaluation of first pass effect and biliary excretion of diperdipine in the dog. Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):185-90. DOI:10.1007/BF03190202 [3] Herzog R, et al. Experimental studies on the toxicity of diperdipine following oral and parenteral application. Arzneimittelforschung. 1995 Mar;45(3):240-5. PMID:7741776 |
|
Company Name: |
BOC Sciences
|
Tel: |
|
Website: |
https://www.bocsci.com |
Company Name: |
MedChemExpress
|
Tel: |
021-58955995 |
Website: |
www.medchemexpress.com |
|